Q3 EPS Estimate for Zevra Therapeutics Increased by Analyst

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) – Stock analysts at Roth Capital increased their Q3 2025 earnings estimates for shares of Zevra Therapeutics in a research note issued on Wednesday, August 13th. Roth Capital analyst J. Aschoff now expects that the company will post earnings of ($0.03) per share for the quarter, up from their prior forecast of ($0.04). The consensus estimate for Zevra Therapeutics’ current full-year earnings is ($1.95) per share. Roth Capital also issued estimates for Zevra Therapeutics’ Q4 2025 earnings at ($0.01) EPS, FY2026 earnings at $0.86 EPS, FY2027 earnings at $1.63 EPS, FY2028 earnings at $2.05 EPS and FY2029 earnings at $2.48 EPS.

ZVRA has been the topic of a number of other research reports. JMP Securities lowered their target price on shares of Zevra Therapeutics from $19.00 to $18.00 and set a “market outperform” rating on the stock in a report on Wednesday. Wall Street Zen downgraded shares of Zevra Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Sunday, July 20th. Cantor Fitzgerald raised their price target on shares of Zevra Therapeutics from $25.00 to $29.00 and gave the company an “overweight” rating in a report on Thursday, July 10th. HC Wainwright assumed coverage on shares of Zevra Therapeutics in a report on Wednesday, July 2nd. They issued a “buy” rating and a $26.00 price target for the company. Finally, Citigroup reissued an “outperform” rating on shares of Zevra Therapeutics in a report on Wednesday. Nine equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, Zevra Therapeutics has an average rating of “Buy” and an average price target of $23.71.

Zevra Therapeutics Trading Up 6.0%

Shares of ZVRA stock opened at $9.43 on Friday. The company’s fifty day simple moving average is $10.56 and its two-hundred day simple moving average is $8.75. The company has a debt-to-equity ratio of 0.52, a current ratio of 7.85 and a quick ratio of 2.93. Zevra Therapeutics has a 1 year low of $6.19 and a 1 year high of $13.16. The stock has a market capitalization of $529.31 million, a price-to-earnings ratio of -44.90 and a beta of 1.87.

Zevra Therapeutics (NASDAQ:ZVRA) last issued its earnings results on Tuesday, August 12th. The company reported ($0.06) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.43 by ($1.49). Zevra Therapeutics had a net margin of 4.33% and a negative return on equity of 112.40%. The business had revenue of $25.88 million for the quarter, compared to the consensus estimate of $22.49 million.

Hedge Funds Weigh In On Zevra Therapeutics

A number of institutional investors have recently made changes to their positions in the stock. Woodline Partners LP increased its holdings in shares of Zevra Therapeutics by 11.5% in the 1st quarter. Woodline Partners LP now owns 4,615,625 shares of the company’s stock worth $34,571,000 after buying an additional 476,032 shares during the last quarter. Adage Capital Partners GP L.L.C. increased its holdings in shares of Zevra Therapeutics by 15.2% in the 2nd quarter. Adage Capital Partners GP L.L.C. now owns 4,168,000 shares of the company’s stock worth $36,720,000 after buying an additional 550,000 shares during the last quarter. Rubric Capital Management LP increased its holdings in shares of Zevra Therapeutics by 60.8% in the 2nd quarter. Rubric Capital Management LP now owns 1,958,318 shares of the company’s stock worth $17,253,000 after buying an additional 740,584 shares during the last quarter. Altium Capital Management LLC increased its holdings in shares of Zevra Therapeutics by 8.8% in the 4th quarter. Altium Capital Management LLC now owns 1,850,000 shares of the company’s stock worth $15,429,000 after buying an additional 150,000 shares during the last quarter. Finally, AIGH Capital Management LLC boosted its stake in shares of Zevra Therapeutics by 82.4% in the 1st quarter. AIGH Capital Management LLC now owns 1,438,109 shares of the company’s stock valued at $10,771,000 after purchasing an additional 649,495 shares in the last quarter. Institutional investors own 35.03% of the company’s stock.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.